Event-related potential correlates of functional hearing loss: Reduced P3 amplitude with preserved Nl and N2 components in a unilateral case

Abstract A female patient exhibiting functional hearing loss in her left ear demonstrated reduced amplitude of P3 component in event-related potentials (ERP) to left monaural stimulation, with preserved N1 and N2 components to stimulation of either ear. This result suggested that stimuli in the affected ear were conducted successfully up to the auditory cortex but that further processing in higher brain regions was 'repressed'. Event-related potential examination for such hysterical disorders could be useful in clarifying their brain mechanism and offer a useful diagnostic clue to its nature.     

Symptoms Predictive for Efficacy of Naftopidil in Patients with Benign Prostate Hyperplasia

Objectives: To evaluate the lower urinary tract symptoms predicting the efficacy of the α1‐adrenoreceptor (AR) antagonist naftopidil in patients with benign prostate hyperplasia. Methods: The efficacy of naftopidil was examined on the basis of changes in the international prostate symptom score (IPSS). All patients received naftopidil (50 mg/day) for 12 weeks. We defined a “responder” as a patient whose total IPSS improved by five or more points and assessed the lower urinary tract symptoms predicting the efficacy of treatment by performing multivariate and probit analyses. Results: Among 132 patients whose data could be analyzed, the efficacy rate was 50.8%. All IPSS items except the urgency score were significantly higher in the responders than the non‐responders before treatment, and all IPSS items were lower in the responders after treatment. In the responder group, significant improvements were observed in the total IPSS score, quality of life (QOL) index, maximum flow rate (Q_max), residual urine volume, and all IPSS items after treatment. In contrast, in the non‐responder group, no parameter except the QOL index improved significantly. The probit analysis demonstrated that the score for weak stream (≥3) or nocturia (≥4) in the IPSS were factors predicting an effective response to naftopidil treatment. Conclusions: Weak stream and/or nocturia are the key symptoms that predict the efficacy of naftopidil treatment in patients with benign prostatic hyperplasia. Those with a score of ≥3 for weak stream or of ≥4 for nocturia are expected to achieve a good response in the subjective symptoms with administration of naftopidil.     

The Specificity of the Penetrating and the Superficial Spreading Types of Early Gastric Cancer—Classification of Early Gastric Cancer Using the Interactive Image Analysis System—

Abstract: Specific types of early gastric cancer were investigated in accordance with the cancer surface area and the degree of penetration by means of quantitative measurements of the surface area of early gastric cancer using the interactive image analysis system. The results indicated a significant correlation between the surface area and the penetration depth in ordinary early gastric cancer. However these correlations were not observed in both well and poorly differentiated adenocarcinoma cases of the so-called PEN and SUPER types, which showed a significant specificity when compared with ordinary early gastric cancer. The PEN and SUPER types of early gastric cancer also exhibited various clinicopathological characteristics, and it was suggested that the poorly differentiated PEN type might be the initial lesion of a linitis plastica type gastric cancer. Examination of the conditions of the mucosa surrounding the cancer revealed a difference between the PEN and the SUPER types, and this suggested that the environment at the site of a cancer growth influences the type of growth and the spread of early gastric cancer.     

Effects of the Pacing Site, Procainamide, and Lead Configuration on the Relationship Between the Upper Limit of Vulnerability and the Defibrillation Threshold

FAN, W., et.al .: Effects of the Pacing Site, Procainamide, and the Lead Configuration on the Relationship Between the Upper Limit of Vulnerability and the Defibrillation Threshold . In six open chest dogs, we determined the upper limit of vulnerability (ULV) and defibrillation threshold (DFT) by an up-down algorithm when the pacing site was at the right atrium, at the left ventricular apex, and at the left ventricular base. Monophasic shocks (6 ms) were given to epicardial patches at 20 and 40 ms before the peak of the T wave to bracket the mid-upslope. In an additional six closed-chest dogs, we determined the ULV and the DFT with transvenous leads with an 8-ms biphasic waveform. The S₁ pacing site was at the right ventricular apex and the right atrium, and the shocks were given at 20 ms and 40 ms before the peak of the T wave, and on the peak of T wave. The same test was repeated after intravenous procainamide infusion (20 mg/Kg loading, then 2 mg/min maintenance). In the first six dogs, the ULV determined when pacing was given to the left ventricular apex, the left ventricular base, and the right atrium was 4.2 ± 1.7 J, 4.4 ± 2.1 J, and 3.9 ± 1.5 J, respectively; values that were not significantly different from the DFT of 4.8 ± 1.9 J, 4.5 ± 1.9 J, and 4.2 ± 1.3 J, respectively. In the latter six dogs, the ULV versus the DFT was 13.5 ± 5.2 J versus 18.2 ± 6.2 J (right ventricular apex) and 12.8 ± 6.0 J versus 15.4 ± 6.0 J (right atrium) at baseline; 14.6 ± 4.6 J versus 19.5 ± 6.7 J (right ventricular apex) and 14.3 ± 5.5 J versus 18.7 ± 6.4 J (right atrium) during procainamide infusion (P = NS for all). We conclude that, when tested with 2–3 shocks on or before the peak of the T wave, the ULV can be used to estimate the DFT with both epicardial patch and transvenous lead configurations. Different S₁ pacing sites and procainamide did not change the relationship between the ULV and the DFT.     

Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder

BACKGROUND: The objective of this study was to retrospectively investigate the effectiveness of transurethral resection of bladder tumor (TURBT) and intravesical instillation therapy for stage T1, grade 3 (T1G3) transitional cell carcinoma (TCC) of the urinary bladder. METHODS: Between January 1995 and December 1997, 97 patients with T1G3 TCC of the urinary bladder were treated by TURBT and adjuvant intravesical instillation with bacillus Calmette-Guérin (BCG) or other anticancer agents. The recurrence-free survival rates were evaluated according to several clinicopathological factors. The cases that progressed to muscle invasive disease were also analysed. RESULTS: In this series, the median follow-up period was 25 months (range, 5- 41) after the initial TURBT. Intravesical recurrence was noted in 44 patients (45%), and the 1, 2, and 3 year recurrence-free survival rates were 72%, 58%, and 42%, respectively. Multivariate analyses revealed that the risk of intravesical recurrence was significantly higher for patients who did not receive BCG therapy, irrespective of age, gender, tumor size, multiplicity, pathological stage, concomitant carcinoma in situ, and lymphovascular involvement. Moreover, after a median of 10 months, disease progression occurred in seven patients (7%), of which only one patient was treated by BCG therapy after initial TURBT. CONCLUSION: These findings suggest that intravesical instillation with BCG combined with TURBT is an effective conservative treatment for T1G3 TCC of the bladder. Patients with negative prognostic factors should be treated by BCG rather than other anticancer agents after TURBT.     

Bone Marrow‐Derived Cells Implanted into Freeze‐Injured Urinary Bladders Reconstruct Functional Smooth Muscle Layers

Regenerative medicine offers great hope for lower urinary tract dysfunctions due to irreversibly damaged urinary bladders and urethras. Our aim is the utilization of bone marrow‐derived cells to reconstruct smooth muscle layers for the treatments of irreversibly damaged lower urinary tracts. In our mouse model system for urinary bladder regeneration, the majority of smooth muscle layers in about one‐third of the bladder are destroyed by brief freezing. Three days after wounding, we implant cultured cells derived from bone marrow. The implanted bone marrow‐derived cells survive and differentiate into layered smooth muscle structures that remediate urinary dysfunction. However, bone marrow‐derived cells implanted into the intact normal urinary bladders do not exhibit these behaviors. The presence of large pores in the walls of the freeze‐injured urinary bladders is likely to be helpful for a high rate of survival of the implanted cells. The pores could also serve as scaffolding for the reconstruction of tissue structures. The surviving host cells upregulate several growth factor mRNAs that, if translated, can promote differentiation of smooth muscle and other cell types. We conclude that the multipotency of the bone marrow‐derived cells and the provision of scaffolding and suitable growth factors by the microenvironment enable successful tissue engineering in our model system for urinary bladder regeneration. In this review, we suggest that the development of regenerative medicine needs not only a greater understanding of the requirements for undifferentiated cell proliferation and targeted differentiation, but also further knowledge of each unique microenvironment within recipient tissues.     

Expression of thymidine phosphorylase in human superficial bladder cancer

BACKGROUND: The purpose of the present paper was to investigate the expression level of thymidine phosphorylase (TPase) in superficial bladder cancer tissues obtained by transurethral resection, and determine whether its expression correlates with tumor recurrence. METHODS: From March 1998 to December 2001, 99 patients with superficial bladder cancer were diagnosed and treated at eight affiliated hospitals. Tissue specimens obtained by transurethral resection of superficial bladder cancer (TURBT) were applied to immunohistochemical study using anti-TPase antibody as well as pathological diagnosis. The data were subjected to statistical analysis. RESULTS: Using MoAb 654-1 as the primary antibody, TPase was clearly stained in human bladder cancer tissues. The maximum TPase level measured by enzyme-linked immunosorbent assay (ELISA) method in normal bladder tissues was 18.7 U/mg protein. The TPase activity was 2.8-fold higher in tumors than in normal bladder samples (P = 0.037). The TPase positivity rates determined by immunohistochemical and ELISA methods were distinctly correlated (P = 0.046). For the recurrence-free rates in pT1 tumors treated by TURBT alone (n = 46), there were no statistically significant differences between Tpase-positive or -negative cases. CONCLUSIONS: The TPase expression determined by ELISA and immunohistochemistry is significantly up-regulated in superficial bladder tumors compared with normal bladder samples. However, TPase expression by immunohistochemistry is not a predictive index of recurrence-free rate for superficial bladder cancer treated with TURBT alone.     

Genetic analysis of a Japanese patient with butyrylcholinesterase deficiency

A patient (64-year-old, male) with familial cholinesterasemia caused by BChE deficiency was studied. DNA sequence analysis of all exons identified a point mutation, an A→G transition at codon 128, resulting in a Tyr→Cys substitution. The propositus showed extremely low BChE activity, but his other family members (three individuals) showed from intermediate to normal BChE activity. An immunological method revealed the absence of BChE protein in serum of the propositus. Both PCR primer introduced restriction analysis (PCR-PIRA) and sequence analysis revealed all three family members to be heterozygotes for this mutation.     

Testicular Toxicity of Gallium Arsenide, Indium Arsenide, and Arsenic Oxide in Rats by Repetitive Intratracheal Instillation

The testicular toxicities of two compound semiconductor materials,gallium arsenide (GaAs) and indium arsenide (InAs), and arsenicoxide (As₂O₃) were examined in rats by repetitive intratrachealinstillation of these substances in suspension twice a week,a total of 16 times. A single instillation dose was 7.7 mg/kgin the GaAs and the InAs groups and 1.3 mg/kg in the As₂O₃ group.A significant decrease in sperm count and significant increasein the proportion of morphologically abnormal sperm were foundin the epididymis in the GaAs group. Especially, abnormal spermwith a straight head increased markedly in this group. In theGaAs–treated rats, there was 40-fold increase in the degeneratinglate elongated spermatids at the postspermiation stages, stagesIX, XI, and XI. From these results, it is indicated that GaAsdisturbed the spermatid head transformation at the late spermiogenicphases and caused spermiation failure. InAs caused a sperm countdecrease in the epididymis, though its testicular toxicity wasrelatively weak compared with that of GaAs. As₂O₃, a probabledissolution arsenic product of GaAs and InAs in vivo, did notshow any testicular toxicities in this study. It seems likelythat, along with arsenics, gallium and indium play a role inthe testicular toxicities of GaAs and InAs.